Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

We estimate the company's R&D expense to increase 11.2% in 2025. Globus Medical merged its business with NuVasive. The combined company has formed a global musculoskeletal company focused on rapid ...

The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal market, unlocking a $2.5 billion market opportunity. This strategic move positions Globus to further add to ...

Globus Medical has been actively pursuing strategic acquisitions to enhance its market position and product offerings. The company successfully completed its merger with NuVasive (NASDAQ:NUVA), ...

We estimate the company's R&D expense to increase 11.2% in 2025. Globus Medical merged its business with NuVasive. The combined company has formed a global musculoskeletal company focused on rapid ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...